M&A Deal Summary

Biocodex USA Acquires Hilma

On November 17, 2022, Biocodex USA acquired life science company Hilma

Acquisition Highlights
  • This is Biocodex USA’s 3rd transaction in the Life Science sector.
  • This is Biocodex USA’s 2nd transaction in the United States.
  • This is Biocodex USA’s 1st transaction in New York.

M&A Deal Summary
Date 2022-11-17
Target Hilma
Sector Life Science
Buyer(s) Biocodex USA
Deal Type Add-on Acquisition

Target

Hilma

New York, New York, United States
Hilma makes natural remedies that actually work for health issues like digestion, head tension, immune support, and more. The company makes natural remedies accessible to the mainstream customer, who has embraced natural products in food, beauty, and household items, and is looking for an effective natural option for their medicine cabinet. Hilma is entirely female-founded and led. Hilma was formed in 2020 and is based in New York, New York.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Biocodex USA

Redwood City, California, United States
Category Company
Founded 1953
Sector Life Science
DESCRIPTION

Biocodex USA is an independent multinational pharmaceutical company, dedicated to providing its customers with meaningful health care solutions, with an emphasis on gastroenterology and oncology supportive care.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 3 of 3
Type (Add-on Acquisition) 2 of 2
State (New York) 1 of 1
Country (United States) 2 of 2
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-11-18 Laboratoires IPRAD

Paris, France

Laboratoires IPRADParis is a pharmaceutical company. Feminine Care, with the brands Saforelle®, Mucogyne®, Gestarelle®, Physioflor®, and gynecological drugs like Secnol® and Gydrelle®. Laboratoires IPRAD was founded in 1989 and is based in Paris, France.

Buy -
Mergr

Product

Company

Legal